Compare Novartis AG (NVS) vs Wolfspeed Inc (WOLF) Price & Performance

Novartis AGTrade

Wolfspeed IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Wolfspeed Inc — how do they compare? Novartis AG trades at $149.81 (market cap $290.25B), while Wolfspeed Inc trades at $32.39 (market cap $1.53B). The key difference: Novartis AG is far larger — about 189.7× Wolfspeed Inc's market cap, and Novartis AG pays a 3.17% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals.

	NVS	WOLF
Market Cap	$290.25B	$1.53B
Sector	Health	Technology
52-Week High	$168.62	$73.68
52-Week Low	$113.50	$1.19
Enterprise Value	$330.27B	$2.19B
Dividend Yield	3.17%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

No Aura AI signal available yet.

Wolfspeed Inc

WOLF trades at $29.38, down 1.71% with bearish technical signals despite oversold RSI readings. The company shows negative profitability metrics with -79.83% net income margin and -14.54% ROE, though recent earnings beat expectations in two of three quarters. Strategic shifts toward data centers and defense markets alongside patent litigation activity create mixed sentiment.

Outlook remains challenging due to persistent losses and competitive pressures, though analyst consensus leans slightly bullish with 31.58% buy ratings. Key risks include execution on margin improvement and market share battles in the competitive semiconductor space.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 22 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

WOLF

Wolfspeed shows long-term potential in AI silicon carbide market despite recent volatility and bankruptcy historySeeking Alpha · 1 day agoBullish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Wolfspeed Inc

Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.